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Summary 
Ferrochelatase, the catalyst for the last step in heme synthesis, is 
induced by chronic phenobarbital administration and this induction is pre- 
vented by the simultaneous administration of cycloheximide. This induction 
is revealed when the pyridine hemochrome was measured under anaerobic con- 
ditions but cobalt chelatase activity in hepatic mitochondria was not in- 
creased by phenobarbital. Furthermore, certain metals inhibited ferrochela- 
tase activity but had no effect on cobalt chelatase. Although both delta 
aminolevulinic acid synthetase and ferrochelatase are located in a similar 
region in the mitochondria, the time course of induction for ferrochelatase 
is different than that observed for delta aminolevulinic acid synthetase. 
One of the earliest measurable responses to inducers of microsomal 
mixed function oxidase reactions is the induction of delta aminolevulinic 
acid synthetase (ALAS), the catalyst for the first step in heme synthesis 
(1,2,X). Within 2 hours after the administration of phenobarbital or 3,4- 
benzpyrene significant increases in ALAS are observed (3) which coincide 
with increased incorporation of glycine-2- 14 C into microsomal heme and which 
precede elevations in microsomal protoheme, P-450 and certain microsomal 
oxidations. Since ALAS and ferrochelatase (protoheme ferrolyase) are both 
associated with the inner membrane of the mitochondrion (4,5) and since 
ferrochelatase mediates the critical last step in heme synthesis, it was of 
interest to examine whether it is induced by phenobarbital and, if so, 
whether it would be increased at a rate which is similar to the rate of in- 
crease of ALAS. This report shows that phenobarbital induces ferrochelatase 
activity, but at a time course different than that observed for ALAS, and 
that this induction is not observed when cobalt chelatase activity was 
measured. 
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Methods and Materials 
Sprague-Dawley, male rats weighing 50 grams were used in all studies. 
Water was allowed ad libitum but animals were fasted for 24 hours prior to -- 
sacrifice. Sodium phenobarbital was given at a daily dose of 60 mg/kg and 
cycloheximide was employed at a dose of 1 mg/kg and 2 mg/kg, 48 and 24 
hours before sacrifice. 
Ferrochelatase activity was studied using rat liver mitochondria pre- 
pared as described by Jones and Jones (4) except that glycine buffer was 
substituted for Tris buffer used by those investigators. Mitochondrial pel- 
lets were suspended finally in 0.25 M sucrose-O.1 M glycine buffer, pH 8.0. 
Tris buffer was not employed because a spectrum was produced non-enzymatical- 
ly with cobalt at wavelengths which were used to measure the activity of 
the enzyme. 
Two assays were used to study the activity of the enzyme. The aero- 
bic formation of cobalt-protoporphyrin IX complex was measured at 430 mp 
in a Shimadzu split beam spectrophotometer. Reaction mixtures were com- 
posed of protoporphyrin IX, 50pM; cobalt, 50 PM; Tween 80, 0.1%; mitochon- 
dria, l-4 mg protein per milliliter of reaction mixture and glycine buffer, 
0.1 M, pH 7.8. At 37O, the increase in absorbance at 430 mpwas linear with 
protein concentration up to 4 mg/ml of reaction mixture and 75 minutes of 
incubation (Figure 1). Boiled enzyme and the omission of either cobalt or 
protoporphyrin IX yielded no absorbance bands. Control reactions were 
usually carried out without cobalt until measurements were desired, at 
which time cobalt chloride was added and spectral measurements were taken. 
In the second assay system the formation of the pyridine hemochrome 
was measured from ferrous ion and protoporphyrin IX under a nitrogen atmo- 
sphere in the presence of rat liver mitochondria. This is the method 
described by Porra and Jones (6) except that reduced glutathione was 
omitted from reaction mixtures. Its omission appeared not to affect 
results reported here. Assays were conducted while product formation was 
linear with time and protein concentrations. 
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Figure 1. The formation of cobalt-protoporphyrin IX complex in rat liver 
mitochondria. Reactions were carried out aerobically at 37' and they con- 
tained 50 PM protoporphyrin IX, 50 PM cobalt chloride, 0.1% Tween SO, mito- 
chondria, 2 mg/ml of reaction mixture and glycine buffer, 0.1 M, pH 7.8. 
The spectra were measured on a Shimadzu split beam recording spectrophoto- 
meter with the blank reaction having cobalt added just prior to recording. 
TABLE 1 
Effect of certain metals on ferrochelatase activity 
and cobalt chelatase activity 
Metal Ion Concentration 
(Ml 
Per Cent Inhibition 
Iron Method Cobalt Method 
cu++ 10 -4 52 6 
Ni 3-f 10 
-4 
67 0 
Reactions were carried out as described in Methods and Materials. 
Chloride salts were employed where indicated and chloride ion itself was 
shown not to have any effects. 
Results 
Several series of studies such as lability on heating, pH optima and 
stimulation of activity by ether (7) gave responses in a similar direction 
519 
Vol. 40, No. 3,197O BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 
whether the enzyme was measured by the cobalt or iron assay. Previously, 
the distribution of cobalt and ferrochelatase activity had been shown to be 
similar (4). However, it was surprising to find that a differential sensi- 
tivity existed to certain metals such as copper and nickel. Table 1 shows 
that when cupric ion or nickel was used in reaction mixtures there was a 
marked inhibition of the formation of the pyridine hemochrome while no ef- 
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Figure 2. The effect of phenobarbital administration on rat liver mito- 
chondrial ferrochelatase. Male, Sprague-Dawley rats (50 grams) were treated 
with phenobarbital sodium (60 mg/kg) at the arrows (solid line) or saline 
(dashed line). Activity was measured by the pyridine hemochrome assay (7) 
except that reduced glutathione was omitted from the reaction. Each point 
represents the mean value + S.E.M. of 4 animals. - 
Figure 2 shows the effect of chronic phenobarbital treatment on rat 
hepatic mitochondrial ferrochelatase activity. No increase in activity was 
seen when the cobalt assay was employed but when the activity was measured 
by the pyridine hemochrome formation a marked enhancement of activity was 
observed. At 72 hours after phenobarbital treatment a 4-fold increase in 
specific activity was observed. This stimulation of ferrochelatase activity 
by phenobarbital is inhibited by the simultaneous administration of cyclo- 
heximide (Table 2) but the addition of phenobarbital to incubation mixtures 
did not alter enzymatic activity. This indicates that the effect of pheno- 
barbital is probably mediated through an increase in protein synthesis. 
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TABLE 2 
The effect of cycloheximide on the induction of ferrochelatase activity 
produced by phenobarbital treatment. 
Treatment Ferrochelatase Activity 




Phenobarbital + Cycloheximide 0.16 
Pyridine hemochrome formation was used to study ferrochelatase acti- 
vity as described in Methods and Materials. Phenobarbital sodium (60 mg/kg) 
and cycloheximide (1 mg/kg and 2 mg/kg) were injected into rats 48 and 24 
hours prior to sacrifice. Control rats received injections of saline. 
Discussion 
These studies document an induction of rat hepatic mitochondrial 
ferrochelatase by the chronic treatment of rats with phenobarbital. How- 
ever, this enhancement of activity was observed only when pyridine hemo- 
chrome formation was measured and not when the formation of the cobalt 
protoporphyrin IX complex was examined. Previously, we had observed the 
insensitivity of cobalt chelatase activity to copper and nickel, metals 
which inhibited pyridine hemochrome formation. Since other investigators 
(5) have used cobalt as a substrate for this reaction, attention is drawn 
to the dissociation of these activities, and since ferrous ion is considered 
to be the physiologic substrate it is suggested that the pyridine hemo- 
chrome assay is more truly representative of ferrochelatase activity. One 
likely explanation for this dissociation is that a different enzyme mediates 
cobalt complexation. However, one cannot exclude the possibility that a 
metal carrier system for iron is being affected with phenobarbital treatment 
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and with certain metals but that no carrier or a different carrier is re- 
quired for cobalt transport to the enzyme. 
It is interesting to note that the temporal response of ferrochelatase 
activity after phenobarbital administration is quite different than that 
observed with ALAS activity. ALAS activity increases markedly and rapidly 
in rat liver after phenobarbital administration reaching a maximum at 12 
hours (1800% of control) followed by a return toward the normal level after 
2-4 days of treatment (3). One may suggest that the ALAS activity and 
ferrochelatase are reciprocally related and that increases in ferrochelatase 
activity are promoted through increased flux of porphyrin substrate brought 
about by increased ALAS activity. In turn, the increased heme formed by 
these events may be responsible for the decreases in ALAS activity upon 
prolonged phenobarbital administration. It has been suggested by Granick 
and his colleagues (8,9,10) that heme participates in the regulation of 
the synthesis of ALAS on the basis of a feedback repression. Also, Schol- 
nick et al. (11) have described the direct inhibition of soluble ALAS by -- 
heme which could account for another manner of control of heme synthesis in 
the mammal. It is also possible that the synthesis of ALAS and ferrochelatase 
are independent of each other and that the turnover of ferrochelatase is 
much slower than that of ALAS. 
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